Drugs / 15O-water
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01246869 | Mar 2013 → May 2014 | brain cancer | University of Utah | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01502228 | Oct 2011 → Feb 2014 | renal cell carcinoma | Indiana University | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00714142 Comparator | Aug 2008 → Apr 2009 | kidney failure, renal artery obstruction | Jeffrey L. Lacy | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 15O-water | “Administer 15O-water at 50 mCi/dose, IV.” NCT01502228 ↗ |
| Modality | Diagnostic / imaging agent | “Using positron emission tomography (PET scan) the researchers can see the tracer and can learn more about how the blood moves through the kidneys.” NCT00714142 ↗ |
| Route | Intravenous | “10-20 mCi, IV” NCT00714142 ↗ |